Immune-related Gene Prognostic Index (IRGPI) for Lung Adenocarcinoma Predicts Patient Prognosis and Immunotherapy Response

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2023 Nov 16

PMID 37970331

Authors

Zheng Zhu

Wei Feng

Xiao-Yan Tan

Pin-Chao Gu

Wei Song

Hai-Tao Ma

Affiliations

Soon will be listed here.

Abstract

Objective: We searched for a predictive biomarker that also predicts whether patients would benefit from immune checkpoint blockade (ICB) treatment from a few angles, because existing biomarkers no longer wholly replicate the interconnections of distinctive elements in the tumor microenvironment (TME).

Methods: We identified 55 pivotal IRGs by performing a WGCNA and univariate Cox regression analysis on a lung adenocarcinoma dataset from the TCGA database. The IRGPI model was then constructed using multivariate Cox regression analysis, which identified 16 genes and verified the use of the GSE68465 database. The AUC of the IRGPI was compared to those of the current biomarkers to determine its predictive potential. Then we examined the molecular and immunological properties of ICB and assessed its effectiveness using CTLA4 expression and TIDE.

Results: Patients with a high IRGPI had a later clinical stage, more severe symptoms, and a worse prognosis. Patients with a low IRGPI had a higher immune escape potential and were less responsive to immunotherapy.

Conclusion: The IRGPI may be a biomarker for determining the prognosis of patients and whether they respond favorably to ICB therapy.

References

Yang W, Hsu F, Yang P . Precision radiotherapy for non-small cell lung cancer. J Biomed Sci. 2020; 27(1):82. PMC: 7374898. DOI: 10.1186/s12929-020-00676-5. View

Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C . Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52(2):177-186. DOI: 10.1038/s41588-019-0569-6. View

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View

Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View

Ming J, Zhang Q, Qiu X, Wang E . Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. Eur J Cancer. 2009; 45(5):866-73. DOI: 10.1016/j.ejca.2008.12.006. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(5):497-530. DOI: 10.6004/jnccn.2022.0025. View

Olivera A, Beaven M, Metcalfe D . Mast cells signal their importance in health and disease. J Allergy Clin Immunol. 2018; 142(2):381-393. DOI: 10.1016/j.jaci.2018.01.034. View

Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q . Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018; 24(7):978-985. DOI: 10.1038/s41591-018-0045-3. View

Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-9. PMC: 3967235. DOI: 10.1038/nature10673. View

10.

Suzuki K, Kadota K, Sima C, Nitadori J, Rusch V, Travis W . Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2012; 31(4):490-8. PMC: 3731922. DOI: 10.1200/JCO.2012.45.2052. View

11.

Shen S, Wang G, Zhang R, Zhao Y, Yu H, Wei Y . Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. EBioMedicine. 2018; 40:318-326. PMC: 6412087. DOI: 10.1016/j.ebiom.2018.12.054. View

12.

Vokes N, Chambers E, Nguyen T, Coolidge A, Lydon C, Le X . Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2022; 17(6):779-792. PMC: 10478031. DOI: 10.1016/j.jtho.2022.02.011. View

13.

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

14.

Parma B, Ramesh V, Gollavilli P, Siddiqui A, Pinna L, Schwab A . Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. J Exp Clin Cancer Res. 2021; 40(1):248. PMC: 8348813. DOI: 10.1186/s13046-021-02049-8. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Murray P . Immune regulation by monocytes. Semin Immunol. 2018; 35:12-18. DOI: 10.1016/j.smim.2017.12.005. View

17.

Zhang Y, Cedervall J, Hamidi A, Herre M, Viitaniemi K, DAmico G . Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis. Cancer Res. 2020; 80(16):3345-3358. DOI: 10.1158/0008-5472.CAN-19-3533. View

18.

Chen Y, Li Z, Zhou G, Sun Y . An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2020; 27(1):330-341. DOI: 10.1158/1078-0432.CCR-20-2166. View

19.

Liu Y, Zhang X, Yang B, Zhuang H, Guo H, Wei W . Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC. Cancer Res. 2018; 78(9):2219-2232. DOI: 10.1158/0008-5472.CAN-17-2432. View

20.

Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q . Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer. 2012; 131(10):2456-64. PMC: 4012336. DOI: 10.1002/ijc.27529. View